TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: postoperative sleep quality of one night before surgery
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: postoperative sleep quality of the first night after surgery
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: postoperative sleep quality of the third night after surgery
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Set of Antibodies Most Frequently Bound to Red Blood Cells (RBCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to catheter failure event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: MRD-neg CR/CRi at end of cycle 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in migraine pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of Vemurafenib in Untreated Brain Metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Normal Color vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stomach symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of hematopoietic cell transplantation (HCT) failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of children recovered from diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of atherosclerotic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of unbound active major metabolite (DHA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of grade 3 or 4 systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of relapse of infection
Endpoint domain: Adverse events/effects
Primary endpoint: Psoriasis Area Severity Index (PASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Tissue perfusion measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of 3 dose levels
Endpoint domain: Adverse events/effects
Primary endpoint: Intracranial progression free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Presence or absence of variant polymorphisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Left Ventricular End-systolic Dimension (LVESD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Surviving Participants
Endpoint domain: Mortality/survival
Primary endpoint: Area under the curve of 95% oxygen desaturation (AUCdesat)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of Infusions With One or More Temporally-associated Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically Significant Changes in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HOMA IR Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CRP Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 24-H Systolic Blood Pressure Mean Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Best overall response rate (BORR) of brain metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 30-day Equivalent Prescribing of Schedule II Controlled Substances
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: serum Lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: eGFR Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Target glucose control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ability to identify US breast findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported experience of cycling-related pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Failure Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Time from Catheterization Lab Arrival to Device Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity defined as grade 3 or 4 GVHD, secondary graft failure, death, or grade 4 organ failure
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Viral Infections in CBT Patients
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Continuous Smoking Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percentage of Heavy Drinking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Invasive Fungal Disease (IFD)
Endpoint domain: Adverse events/effects
Primary endpoint: Intracerebral haemorrhage (ICH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ischaemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardio-vascular death
Endpoint domain: Mortality/survival
Primary endpoint: Conditions during tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reliability of HIP and rHIP test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalization for asthma attack
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Frequency of Alcohol Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response rate of metastatic or recurrent squamous cell carcinoma of the esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: number of subjects with drug-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Cancer Antigen-125
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in blood gas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: aberrant cryptic foci (ACF) multiplicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Technical feasibility of electronical monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient benefit measured with SPADI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient benefit measured with Constant Murley score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient benefit measured with QuickDASH
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient benefit measured with SF-36 mental score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Predictive ability of migraine attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial Remission (PR) at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean changes in pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean changes in distance walked during six-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Directional preponderance (DP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exposure to piperacillin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain referred per each zone injected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Post-exercise Coronary Vasodilator Reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Retention in care with viral suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mMIDI (modified Minnesota Impulsive Disorders Interview)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Myocardial Infarction Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Simeprevir (SMV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable (AUC [0-last]) of Simeprevir (SMV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of Simeprevir (SMV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma ion concentrations and osmolarity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Validated Acute Serious Bacterial Infection (VASBI) Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Airway Seal Pressure Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with treatment-related adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Survival at 180 Days
Endpoint domain: Mortality/survival
Primary endpoint: Venous umbilical cord blood concentration of glutathione
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Percent of Mucosa Healed by Neosquamous Epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PD15 FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients treated with antifungal therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Event-free Survival Probability
Endpoint domain: Mortality/survival
Primary endpoint: bactericidal titers & antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Participants With EULAR (Good)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ibuprofen Doses Taken
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Missed Work Hours
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change of Tinnitus status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Tinnitus severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of hearing obstacle average
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: size of wound covered with healthy granulation tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Suicide Ideation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Coping
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change From Baseline in SNAP-IV Rating Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Change From Baseline in Chinese Health Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: total creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: feasibility of exercise intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pharmacokinetic parameters of dexmedetomidine infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Speed of Processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in BODE test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Time to Exhaustion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C3/C5 acylcarnitine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Six Minutes Walking Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Instrumented variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative movements of the spinous processes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers of Thrombosis and Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Caloric test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratios of geometric mean values for pacritinib treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IE therapeutic plan
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in post-prandial glucose (PPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of clinical pharmacist consultations accepted
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Concordance of Genetron Uro V1 assay with TURBT histopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time of eyelash reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time of eye opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State of anxiety evaluated with STAI-YA scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety proneness evaluated with STAI-YB scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Apprehension anxiety evaluated with Penn State Worry Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum tolerated dose of SU5416 and doxorubicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Achieving Eczema Area and Severity Index (EASI-75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cumulative 24-hour pethidine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in oral hygiene status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of BIBW 2992
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of acetylation at serine-529 of platelet COX-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in glomerular filtration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of stroke/systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Pass/fail ratio of in situ simulation assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional outcome of the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite score of TIA treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Overall Vision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 3-months deterioration-free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Reduction in Final OCS Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Adverse Events (AEs) in Part 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with laboratory value abnormalities in Part 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with vital sign abnormalities in Part 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with electrocardiogram (ECG) abnormalities in Part 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with real-time cardiac monitoring abnormalities in Part 1
Endpoint domain: Adverse events/effects
Primary endpoint: age of resolution in immune defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Freedom from Major Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Completion rate of remote cognitive assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion rate of secondary assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Core Biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Urinary Methylnicotinamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: accuracy of 2D transesophageal echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulated time with toxicity (duration)
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulated time with toxicity (prevalence)
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulated time with toxicity (area under the curve)
Endpoint domain: Adverse events/effects
Primary endpoint: Back pain risk stratification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Term Recognition Memory task (accuracy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Titrated Delayed Matching-to-Sample task (accuracy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Continuous Performance task (omission errors)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients with complete or almost complete clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General Clinical Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in subject's readiness and fitness to return to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Frequency of transcutaneous CO2 revealing sleep hypoventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of participants with CDAI score < 150
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with SES-CD score decrease from baseline ≥ 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatal or Non-fatal Stroke/TIA
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Gait Speed at 4 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Step Length at 4 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate to <131>I-MIBG treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutralizing antibody responses (Geometric Mean Titer)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Accuracy of GlucoWatch G2 Biographer and CGMS sensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of mechanical ventilation days after operation until discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in rate of HPV vaccination initiation among 11-12 year olds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in rate of HPV vaccination initiation among those 13-26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intervention Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: change in oral glucose tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: abstinent from alcohol and opioid use, past 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: negative consequences related to substance use
Endpoint domain: Adverse events/effects
Primary endpoint: visual-analogue scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission of Depression (%)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinic based Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subject attrition rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention